Overall market sentiment has been high on IGM Biosciences Inc (IGMS) stock lately. IGMS receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
IGM Biosciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on IGMS!
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With IGMS Stock Today?
IGM Biosciences Inc (IGMS) stock is trading at $5.85 as of 3:13 PM on Wednesday, Nov 15, an increase of $1.01, or 20.87% from the previous closing price of $4.84. The stock has traded between $4.81 and $5.87 so far today. Volume today is 282,275 compared to average volume of 359,679.
To screen for more stocks like IGM Biosciences Inc click here.
More About IGM Biosciences Inc
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
Click Here to get the full Stock Report for IGM Biosciences Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
